Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Current Liabilities (2017 - 2025)

Eton Pharmaceuticals' Total Current Liabilities history spans 8 years, with the latest figure at $38.5 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 92.96% to $38.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $38.5 million, a 92.96% increase, with the full-year FY2025 number at $38.5 million, up 92.96% from a year prior.
  • Total Current Liabilities hit $38.5 million in Q4 2025 for Eton Pharmaceuticals, down from $44.2 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for ETON hit a ceiling of $44.2 million in Q3 2025 and a floor of $3.1 million in Q2 2021.
  • Historically, Total Current Liabilities has averaged $14.9 million across 5 years, with a median of $10.0 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: fell 13.04% in 2022 and later surged 151.52% in 2023.
  • Tracing ETON's Total Current Liabilities over 5 years: stood at $4.6 million in 2021, then skyrocketed by 41.75% to $6.5 million in 2022, then surged by 151.37% to $16.2 million in 2023, then rose by 22.82% to $19.9 million in 2024, then surged by 92.96% to $38.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for ETON at $38.5 million in Q4 2025, $44.2 million in Q3 2025, and $38.6 million in Q2 2025.